Filament Health: 2022 Financials And Operational Highlights From Creator Of The Ayahuasca Pill

The natural psychedelics company responsible for creating the first standardized ayahuasca capsule, Filament Health Corp. FLHLF, shared its financial results and operational highlights for the period ended December 31, 2022.

Numbers show:

  • Total cash of $2.08 (CA$2.8) million as of Dec. 31, 2022, as compared to $3.4 million by Dec. 31, 2021. 

  • Cash starting point of 2022 was $4.6 million, while $652.937 in 2021.

  • R&D expenses nearly doubled, from $354.258 in 2021 to $623.744 in 2022.

  • 2022 saw no expenses in clinical trials compared to the $679.113 spent in 2021, yet a newly acquired licensing revenue of $270.932. 

  • Yearly net and comprehensive loss of $12.1 million compared to $6.8 million the prior year, including total expenses of $4.4 million vs. $6.9 million respectively.  

  • 2022 saw a 2021-inexistent impairment of goodwill for a total $7.9 million.

During the fourth and last quarter of 2022, the company’s milestones included the successful subject dosing in a Canadian psilocybin trial run by ATMA Journey Centers; an academic supply agreement with the Center for Addictions and Mental Health (CAMH); two new patent issuances from the USPTO; and a global licensing agreement with Psyence Group to provide PEX010 (25mg) for clinical trials in palliative care.

See also: Filament Health Shares Q3 2022 Results, On Road To Becoming Industry's Natural Psilocybin Supplier

Moving forward into 2023, Filament created joint venture Magdalena Biosciences Inc. with Jaguar Health Inc. JAGX; has PEX010 participating at two investigator-initiated trials, one for patients with Alcohol Use Disorder (AUD) at Psychiatric Centre Copenhagen and another at the UC-SF’s Translational Psychedelic Research Program for patients with Methamphetamine Use Disorder (MAUD); and finally, inked a second supply agreement with CAMH, this time for PEX010 tested for mild cognitive impairment.

Benzinga’s Psychedelics Capital Conference is almost here! 

April 13th at the Fontainebleau Hotel in Miami Beach will be THE place to set up deals, raise money, meet investors and key partners and learn from the industry’s greatest.

Get your tickets now!

Photo: Benzinga edit with photo by Raimundo79 and Blue Planet Studio on Shutterstock.

Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: CannabisEarningsNewsPenny StocksPsychedelicsManagementMarketsfinancial resultsPsilocybin programPsychedelic-Assisted Therapies
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Cannabis rescheduling seems to be right around the corner

Want to understand what this means for the future of the industry? Hear directly for top executives, investors and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.